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Introduction {#sec1}
============

Caspases are cysteine aspartic proteases with essential roles in programmed cell death ([@bib15]). Previously known as interleukin-1 converting enzyme (ICE), caspase-1 is the prototypic inflammatory caspase ([@bib23], [@bib40]). By promoting the activation of caspase-1, cytoplasmic complexes called inflammasomes control the proteolytic maturation of the pro-inflammatory cytokine interleukin (IL)-1β, which cannot bind the IL-1 receptor in its unprocessed form ([@bib5]). IL-1β lacks a signal peptide, so it cannot be secreted by the conventional pathway via the endoplasmic reticulum and Golgi apparatus. It instead leaves the cell by a poorly understood unconventional secretory pathway engaged by caspase-1. Inflammasome activation results in pyroptosis, a specialized form of lytic, inflammatory cell death defined by its dependence on inflammatory caspases ([@bib15]). Activation of caspase-11 (caspase-4 and caspase-5 in humans) by lipopolysaccharide (LPS) in the cytoplasm also results in pyroptosis ([@bib21]). By forming membrane pores, gasdermin D (GSDMD) executes cell death and IL-1 secretion initiated by inflammatory caspases ([@bib10], [@bib19], [@bib22], [@bib25], [@bib36], [@bib38]).

We previously observed that the secretion of IL-1α by myeloid cells is caspase-1 dependent but insensitive to peptide-based inhibitors of caspase-1 ([@bib17]). IL-1α and IL-1β bind the same receptor (IL1R1), but in contrast to IL-1β, IL-1α is not cleaved by caspase-1 and is active in its full-length form. In the presence of these inhibitors, cleavage of IL-1β is blocked, but IL-1β is secreted in its full-length form. Furthermore, when activated independent of ASC at the NLRC4 or NLRP1 inflammasomes, caspase-1 can induce pyroptosis without processing IL-1β or itself. Peptide-based inhibitors are unable to block this cell death ([@bib6]). Altogether, these results suggested that caspase-1 may have a non-enzymatic or scaffold function that controls secretion of IL-1 and pyroptosis. In support of this concept, pro-inflammatory functions that do not strictly rely on enzymatic activity have also been ascribed to caspase-8 ([@bib20], [@bib24], [@bib30], [@bib39]) and the paracaspase MALT1 ([@bib16]). Furthermore, several mutations in the *CASP1* gene that suppress caspase-1 protease activity have been found in patients with auto-inflammatory conditions that resemble periodic fever syndromes associated with mutations in *NLRP3* or other inflammasome genes ([@bib26]).

These indications that caspase-1 may have a pro-inflammatory function independent of its enzymatic activity prompted us to generate mice deficient for caspase-1 protease activity. With these *Casp1*^*mlt*^ (melted) mice, we demonstrate that in contrast to biochemical inhibition, genetic inactivation of caspase-1 protease activity impairs not only cleavage of IL-1β but also canonical IL-1 secretion and pyroptosis at early time points. Caspase-8 is recruited to the inflammasome and, in caspase-1-deficient cells, drives late, non-canonical maturation of IL-1β ([@bib3], [@bib32]). This phenomenon was also observed in cells expressing enzymatically inactive caspase-1^mlt^. Caspase-8 activation at inflammasomes was suppressed by GSDMD-dependent pyroptosis, rather than caspase-1 protease activity per se. Despite efficient caspase-1-mediated maturation of IL-1β in GSDMD-deficient cells, the rapid, canonical secretion of IL-1β was impaired. However, in the absence of GSDMD-dependent pyroptosis, cells engaged a delayed non-canonical release mechanism that, despite apoptotic caspase activation, was distinct from apoptosis and over time allowed for secretion of equivalent amounts of IL-1β.

Results {#sec2}
=======

Generation and Characterization of *Casp1*^*mlt*^ Mice {#sec2.1}
------------------------------------------------------

An active site cysteine participates in the proteolytic mechanism of caspases, including caspase-1 ([@bib40]). To generate mice lacking caspase-1 protease activity, targeting vectors for the introduction of the inactivating C284A mutation into exon 6 of the murine *Casp1* genomic locus were cloned ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). The mutation changes the genomic sequence from 5′-GCA[TGC]{.ul}CGT-3′ to 5′-GCA[GCG]{.ul}CGT-3′, which translates into the amino acid sequence A[A]{.ul}R instead of A[C]{.ul}R. The mutation also generated a HhaI restriction site (GCGˆC) that was used for screening and genotyping ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

Bone marrow-derived dendritic cells (BMDCs) from mice homozygous for the *Casp1*^*mlt*^ mutation expressed caspase-1 protein at normal levels ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Interbreeding of heterozygous mice produced offspring in the expected Mendelian ratios. Mice homozygous for the *Casp1*^*mlt*^ mutation had growth curves and fertility indistinguishable from their wild-type littermates ([Figures S1](#mmc1){ref-type="supplementary-material"}E--S1H). Immunophenotyping analysis was performed on lymphoid organs of 8-week-old *Casp1*^*mlt/mlt*^ mice and wild-type littermates. *Casp1*^*mlt/mlt*^ mice and wild-type mice had indistinguishable numbers and frequencies of the major immune cell subsets ([Figure S1](#mmc1){ref-type="supplementary-material"}I; data not shown). Patients with mutations in *CASP1* resulting in impaired protease activity display auto-inflammation ([@bib26]). However, under specific pathogen-free (SPF) and specific and opportunistic pathogen-free (SOPF) conditions, mice homozygous for the *Casp1*^*mlt*^ mutation were healthy and did not show obvious signs of spontaneous inflammation or immunosuppression.

Caspase-1 Protease Activity Is Required for Canonical IL-1 Secretion, Pyroptosis, and Innate Immunity to *Francisella* {#sec2.2}
----------------------------------------------------------------------------------------------------------------------

BMDCs from *Casp1*^*mlt/mlt*^ mice secreted comparable amounts of tumor necrosis factor (TNF) and IL-6 upon engagement of various Toll-like receptors and C-type lectin receptors and did not spontaneously secrete these cytokines ([Figure 1](#fig1){ref-type="fig"}A). To genetically test whether caspase-1 protease activity is required for IL-1 secretion and pyroptosis, BMDCs from *Casp1*^*mlt/mlt*^, *Casp1*^−/−^, and wild-type mice were primed with LPS and then treated for up to 3 hr with activators of the NLRP3 (nigericin and imiquimod), AIM2 (poly(dA:dT)), and NLRC4 (*Salmonella enterica* serovar Typhimurium \[*S. typhimurium*\]) inflammasomes. Mature IL-1β, pro-IL-1β, and IL-1α were quantified in the supernatants by ELISA ([Figure 1](#fig1){ref-type="fig"}B), and cell lysates and supernatants were analyzed by immunoblotting ([Figure 1](#fig1){ref-type="fig"}C) for the presence of the cleaved and full-length forms of IL-1β and caspase-1. Lactate dehydrogenase (LDH) activity was measured from supernatants as a readout for pyroptosis ([Figure 1](#fig1){ref-type="fig"}B). Inflammasome activators induced the secretion of cleaved caspase-1 and IL-1β from cells expressing wild-type caspase-1. Similar to *Casp1*^−/−^ cells, *Casp1*^*mlt/mlt*^ cells not only failed to cleave IL-1β but also did not secrete pro-IL-1β or IL-1α and did not undergo pyroptosis at time points up to 3 hr ([Figure 1](#fig1){ref-type="fig"}B). As previously observed ([@bib6], [@bib17]), the peptide-based caspase-1 inhibitor Ac-YVAD-cmk strongly reduced cleavage of IL-1β and caspase-1, but cells treated with this inhibitor still secreted the uncleaved forms of these proteins and underwent pyroptosis ([Figures 1](#fig1){ref-type="fig"}B and 1C). This demonstrates that caspase-1 protease activity is required for early, canonical IL-1 secretion and pyroptosis and suggests that peptide-based caspase-1 inhibitors fail to prevent these outcomes of caspase-1 activity.Figure 1Caspase-1 Protease Activity Is Required for Canonical IL-1 Secretion and Pyroptosis(A) Unprimed BMDCs derived from B6.129-*Casp1*^+/+^ and B6.129-*Casp1*^*mlt/mlt*^ mice were stimulated for 6 hr with different TLR and Dectin-1 agonists as indicated or left unstimulated (medium), and IL-6 and TNF secretion were measured in the supernatants by ELISA (data representative of 3 independent experiments).(B) BMDCs from the indicated mouse strains (B6.129-*Casp1*^*mlt/mlt*^ and B6.129-*Casp1/11*^−/−^) were primed with LPS (50 ng/mL for 3 hr) and subsequently stimulated with agents activating the NLRP3 (nigericin and imiquimod), AIM2 (poly(dA:dT)), and NLRC4 (*Salmonella enterica* serovar Typhimurium) inflammasomes. IL-1β, pro-IL-1β, and IL-1α (top) and LDH (bottom) were quantified from cell-free supernatants by ELISA and a colorimetric assay, respectively.(C) Cleavage and secretion of caspase-1 and IL-1β in BMDCs following inflammasome activation as in (B) were determined by immunoblotting (B6.129-*Casp1*^*mlt/mlt*^).In (A) and (B), mean ± SEM are shown. In (B and (C), data are representative of \>10 independent experiments.

We targeted the caspase-1 allele in both 129 and C57BL/6 embryonic stem cells ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Gene targeting is known to be more efficient in 129 embryonic stem cells, but inactivating mutations in the *Casp11* gene of this strain cannot be segregated from introduced mutations in *Casp1* ([@bib21]). Because B6.129-*Casp1*^*mlt*^ mice were generated several months before B6-*Casp1*^*mlt*^ mice, and because the appropriate controls (the original B6.129-*Casp1*^−/−^ \[ICE^−/−^\] mice that harbor the inactivating *Casp11* mutation) were readily available ([@bib23]), the *in vitro* studies were first performed in B6.129-*Casp1*^*mlt*^ mice ([Figure 1](#fig1){ref-type="fig"}) and then confirmed in B6-*Casp1*^*mlt*^ mice ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). We also generated B6-*Casp1*^−/−^ mice using CRISPR/Cas9 technology to use as controls for B6-*Casp1*^*mlt*^ mice. Previous studies have established a requirement for caspase-1 activation via the DNA-sensing AIM2 inflammasome for innate immunity against the facultative intracellular pathogen *Francisella tularensis* subspecies *novicida* (*F. novicida*) ([@bib13]). Similar to *Casp1*^−/−^ mice, *Casp1*^*mlt/mlt*^ mice from both the C57BL/6 and the 129 backgrounds were susceptible to *Francisella*, displaying an elevated bacterial load in the spleen and liver upon infection ([Figure 2](#fig2){ref-type="fig"}). These results demonstrate that caspase-1 protease activity is required for protection against *Francisella*.Figure 2Caspase-1 Protease Activity Is Required for Innate Immunity to *Francisella*(A--D) Bacterial loads in spleens (A and C) and livers (B and D) of mice infected with *Francisella novicida* for 48 hr were determined by plating serial dilutions of organ homogenates on selective medium plates. In (C) and (D), the wild-type group consists of littermates of B6.129-*Casp1*^*mlt/mlt*^ mice; B6.129-*Casp1*^−/−^ animals were matched by age and sex and were bred in the same isolator. The Mann-Whitney test was used for statistical analysis (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). (A and B) Spleen: *Casp1*^−/−^, p = 0.0317; *Casp1*^*mlt/mlt*^, p = 0.0175; liver: *Casp1*^−/−^, p = 0.0303; *Casp1*^*mlt/mlt*^, p = 0.00012; B6-*Casp1*^−/−^ and littermate B6-*Casp1*^+/+^: n = 5; B6-*Casp1*^*mlt/mlt*^ and littermate B6-*Casp1*^+/+^: n = 7. (C and D) Spleen: *Casp1*^*mlt/mlt*^, p \< 0.0001; liver: *Casp1*^*mlt/mlt*^, p = 0.0076; B6.129-*Casp1*^*mlt/mlt*^ and littermate B6.129-*Casp1*^+/+^: n = 9 and n = 10, respectively; B6.129-*Casp1*^−/−^: n = 4.

Caspase Inhibitors Vary in Their Ability to Prevent GSDMD Cleavage and Pyroptosis {#sec2.3}
---------------------------------------------------------------------------------

Because genetic inactivation of caspase-1 protease activity prevented both IL-1 secretion and pyroptosis at early time points, we examined why peptide-based inhibitors of caspase-1 have a qualitatively different effect. The effect of VX-765, a new peptidomimetic inhibitor of caspase-1 ([@bib43]), on secretion of cleaved IL-1β was comparable to that of Ac-YVAD-cmk ([Figure 3](#fig3){ref-type="fig"}A). In contrast to Ac-YVAD-cmk, VX-765 prevented pyroptosis ([Figure 3](#fig3){ref-type="fig"}A). GSDMD was identified as a cleavage target of caspase-1 and caspase-11 ([@bib1]) required for pyroptosis and IL-1 secretion ([@bib19], [@bib22], [@bib38]). The differential ability of VX-765 and Ac-YVAD-cmk to inhibit pyroptosis was reflected in the prevention of GSDMD cleavage by VX-765, but not by Ac-YVAD-cmk ([Figure 3](#fig3){ref-type="fig"}B). The pan-caspase inhibitor Z-VAD-fmk prevented GSDMD cleavage only at toxic concentrations in which it alone caused release of cytoplasmic proteins, presumably by inducing necroptosis ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}). Consistent with the inability of *Casp1*^*mlt/mlt*^ cells to pyroptose at early time points, GSDMD cleavage was not observed in *Casp1*^*mlt/mlt*^ cells after treatment with inflammasome activators ([Figure 3](#fig3){ref-type="fig"}C). The release of the uncleaved pro-form of IL-1β in the presence of caspase-1 inhibitors at early time points was GSDMD dependent ([Figure 3](#fig3){ref-type="fig"}D). Altogether, these results suggest that VX-765 is a superior caspase-1 inhibitor and that residual cleavage of GSDMD in the presence of Ac-YVAD-cmk is sufficient for pyroptosis and IL-1 release.Figure 3Caspase Inhibitors Vary in Their Ability to Prevent GSDMD Cleavage and Pyroptosis(A) BMDCs were pretreated with the indicated doses of the caspase-1 inhibitors Ac-YVAD-cmk and VX-765 for 30 min and stimulated with 5 μM nigericin for 45 min, and secretion of IL-1β and release of LDH into the supernatant were measured (mean ± SEM are shown).(B) BMDCs were pretreated with caspase inhibitors as indicated and stimulated with nigericin. Caspase-1 and GSDMD cleavage were assessed by immunoblot analysis.(C) BMDCs from wild-type, B6.129-*Casp1*^−/−^, and B6.129-*Casp1*^*mlt/mlt*^ mice were stimulated with nigericin, and GSDMD cleavage was analyzed in cytoplasmic fractions by immunoblotting.(D) BMDCs from the indicated mouse strains (B6.129-*Casp1*^*mlt/mlt*^) were pretreated with caspase inhibitor Z-VAD-fmk (20 μM) or Ac-YVAD-cmk (30 μM) and stimulated with nigericin for 1.5 hr. Secretion of the cleaved and uncleaved forms of IL-1β was assessed by immunoblot analysis from cell-free cell culture supernatants.(A--C) Data representative of ≥3 independent experiments.

Caspase-1^mlt^ Accumulates at the Inflammasome {#sec2.4}
----------------------------------------------

A common feature of inflammasome activation is ASC polymerization and formation of a detergent-insoluble speck ([@bib12]). To determine whether protease activity of caspase-1 influences its ability to be recruited to the ASC speck, wild-type and *Casp1*^*mlt/mlt*^ BMDCs were treated with inflammasome activators, and inflammasome formation was monitored by confocal and super-resolution immunofluorescence microscopy of fixed cells and immunoblotting of the detergent-insoluble fraction of cells. Caspase-1^mlt^ strongly accumulated at the inflammasome or speck ([Figures 4](#fig4){ref-type="fig"}A--4C and [S4](#mmc1){ref-type="supplementary-material"}A), presumably because unlike wild-type caspase-1, it fails to liberate itself by auto-cleavage. Treatment with the caspase-1 inhibitor Ac-YVAD-cmk also caused caspase-1 to accumulate at the inflammasome ([Figure 4](#fig4){ref-type="fig"}A).Figure 4Caspase-1^mlt^ Accumulates at the Inflammasome(A) BMDCs from B6.129-*Casp1*^*mlt/mlt*^ or wild-type mice on culture slides were pretreated with 20 μM Ac-YVAD-cmk where indicated and subsequently stimulated with nigericin. Cells were fixed with paraformaldehyde, stained by immunofluorescence for caspase-1 (green) and ASC (magenta), and analyzed by confocal microscopy. DAPI (blue) localizes with the nuclei. Scale bar represents 20 μm (data representative of \>5 independent experiments).(B) BMDCs from B6.129-*Casp1*^*mlt/mlt*^ or wild-type mice on culture slides, the latter pretreated with 20 μM Ac-YVAD-cmk, were stimulated with nigericin, fixed, and stained by immunofluorescence for caspase-1 (green) and ASC (magenta). ASC specks were visualized at high resolution by STED imaging.(C) BMDCs of the indicated genotypes (B6.129-*Casp1*^−/−^ and B6.129-*Casp1*^*mlt/mlt*^) were primed with LPS and subsequently stimulated with nigericin. An IGEPAL CA-630-insoluble fraction was isolated by centrifugation, and cell lysates, insoluble fractions, and soluble fractions were analyzed for the presence of ASC, caspase-1, and vimentin as fractionation control by immunoblotting. c.l., cell lysate; i.f., insoluble fraction.(D) Four replicates each of BMDCs from B6.129-*Casp1*^*mlt/mlt*^, *Nlrp3*^−/−^, and B6.129-*Casp1*^−/−^ were stimulated and prepared as in (C), and insoluble fraction samples were analyzed by mass spectrometry. The relative enrichment of proteins detected in B6.129-*Casp1*^*mlt/mlt*^ over *Nlrp3*^−/−^ or B6.129-*Casp1*^−/−^ samples is plotted against the inverse relative SD (RSD) within the B6.129-*Casp1*^*mlt/mlt*^ quadruplet (mean/SD).(C and D) Data representative of 2 independent experiments with n = 4 replicates per genotype.

Our results suggested that caspase-1 protease activity is critical for canonical IL-1 secretion and pyroptosis but do not rule out that caspase-1 may have functions that do not strictly require protease activity. The accumulation of caspase-1^mlt^ in the insoluble fraction presented a means to enrich factors that stably interact with caspase-1 at the inflammasome yet avoid potential confounding effects of pyroptosis. Cells of genotypes incapable of caspase-1-dependent pyroptosis were treated with nigericin, and the insoluble fraction ([Figure 4](#fig4){ref-type="fig"}C) was prepared in quadruplicate and analyzed by label-free mass spectrometry. As expected, ASC was consistently enriched in the insoluble fraction of *Casp1*^*mlt/mlt*^ cells relative to *Nlrp3*^−/−^ cells ([Figure 4](#fig4){ref-type="fig"}D). Caspase-1 was also strongly enriched in the insoluble fraction of *Casp1*^*mlt*^ cells relative to *Nlrp3*^−/−^ and *Casp1*^−/−^ cells. However, more than 1,000 other proteins were detected in this cellular fraction, and none of them were reproducibly enriched in an NLRP3- or caspase-1-dependent manner. The strong enrichment of caspase-1 and ASC in this fraction indicates that they are the most abundant components of the inflammasome, but it is clear that better purification techniques will be required to identify potential regulatory components with lower abundance. For example, while caspase-8 can be found in ASC specks ([Figures 5](#fig5){ref-type="fig"}A and 5B) ([@bib35]), it was not detected by mass spectrometry.Figure 5Enhanced Activation of Caspase-8 in Cells Expressing Caspase-1^mlt^(A) BMDCs of the indicated genotypes (B6.129-*Casp1*^*mlt/mlt*^) on culture slides were stimulated with nigericin, fixed, and stained by immunofluorescence for caspase-1 (cyan), caspase-8 (yellow), and ASC (magenta), and then confocal imaging was performed. DAPI (blue) localizes with the nuclei. Scale bar represents 20 μm (data representative of \>5 independent experiments).(B) BMDCs from different *Casp1* genotypes as indicated (B6-*Casp1*^*mlt/mlt*^) and ASC-deficient cells (*Pycard*^−/−^) were investigated for recruitment of caspase-8 into IGEPAL CA-630-insoluble fractions following LPS priming and inflammasome activation by nigericin (for 0.5 or 8 hr) (data representative of 2 independent experiments). c.l., cell lysate; s.f., soluble fraction; i.f., insoluble fraction; h.e., high exposure.(C) Cleavage and secretion of IL-1β and caspase-1 and generation of caspase-8 p18 were monitored by immunoblot analysis 1, 3, and 9 hr after stimulation of BMDCs from the indicated genotypes (B6-*Casp1*^*mlt/mlt*^) with nigericin, imiquimod (70 μM), poly(dA:dT) (1 μg/mL), and *Salmonella enterica* serovar Typhimurium (MOI 20).(D) Secretion of mature IL-1β in conditions as in (C) was measured by ELISA (mean ± SEM are shown).In (C) and (D), data are representative of 5 independent experiments.

Enhanced Activation of Caspase-8 and Non-canonical IL-1β Processing in Cells Expressing Caspase-1^mlt^ {#sec2.5}
------------------------------------------------------------------------------------------------------

Although ASC-containing inflammasomes can recruit caspase-8, the initiator caspase of the extrinsic apoptosis pathway, pyroptosis is the predominant form of cell death in response to inflammasome activators when caspase-1 is present. However, in the absence of caspase-1, caspase-8 is activated at the inflammasome and has been reported to be associated with features of apoptosis ([@bib3], [@bib31], [@bib35]). One possible explanation for the activation of caspase-8 is that in the absence of caspase-1, naked ASC specks can more efficiently recruit caspase-8. However, recruitment of caspase-8 to ASC specks was similar in *Casp1*^*mlt/mlt*^ cells and *Casp1*^−/−^ cells ([Figures 5](#fig5){ref-type="fig"}A, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). This also suggests that caspase-1 and caspase-8 do not compete for the same binding sites at the inflammasome. Consistent with this idea and previous biochemical and structural studies ([@bib14], [@bib41]), caspase-1 and caspase-8 occupied distinct areas in inflammasomes imaged by super-resolution microscopy ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Although most ASC specks in all genotypes displayed some caspase-8 positivity, caspase-8 recruitment was markedly enhanced in the absence of caspase-1 activity ([Figures 5](#fig5){ref-type="fig"}A, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). However, immunoblotting analysis revealed that only a small fraction of the cellular pool of caspase-8 was recruited to the inflammasome ([Figure 5](#fig5){ref-type="fig"}B). This is consistent with previous observations ([@bib35]) and could explain why we did not detect caspase-8 by mass spectrometry. Similarly, the caspase-8 interaction partners cFLIP, FADD, and RIPK1 were also detected in the specks, together with caspase-8, when caspase-1 was absent ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B).

Cleavage of caspase-8 to generate the active p18 fragment was also similar between *Casp1*^−/−^ and *Casp1*^*mlt/mlt*^ cells ([Figures 5](#fig5){ref-type="fig"}B and 5C). This phenomenon required formation of the inflammasome platform, because cleavage of caspase-8 was not observed in the absence of ASC (*Pycard*^−/−^) ([Figure 5](#fig5){ref-type="fig"}B), as reported previously ([@bib3], [@bib31], [@bib35]). Caspase-8 cleavage was readily detected in *Casp1*^−/−^ and *Casp1*^*mlt/mlt*^ cells after 3 hr of inflammasome activation but could also be observed as early as 1 hr after stimulation with nigericin ([Figure 5](#fig5){ref-type="fig"}C). Although caspase-8 is recruited to the ASC speck in wild-type cells ([Figures 5](#fig5){ref-type="fig"}A, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C), cleavage of caspase-8 was not observed in wild-type cells treated with several inflammasome activators for up to 24 hr ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

Caspase-8 can directly cleave IL-1β to generate the mature form ([@bib27]), and caspase-8 activation at the ASC speck in caspase-1-deficient cells can lead to non-canonical (caspase-1-independent) IL-1β maturation after prolonged activation of the inflammasome ([@bib2], [@bib32]). Wild-type cells rapidly secreted cleaved IL-1β as expected ([Figures 5](#fig5){ref-type="fig"}C and 5D). The non-canonical cleavage of IL-1β in *Casp1*^−/−^ and *Casp1*^*mlt/mlt*^ cells correlated with activation of caspase-8 and was inhibited by the pan-caspase inhibitor Z-VAD-fmk and the caspase-8 inhibitor IETD-fmk ([Figures 5](#fig5){ref-type="fig"}C, 5D, and [S5](#mmc1){ref-type="supplementary-material"}D). *Casp1*^−/−^ and *Casp1*^*mlt/mlt*^ cells, but not ASC-deficient cells ([Figure S5](#mmc1){ref-type="supplementary-material"}C), also secreted mature IL-1β after prolonged stimulation with inflammasome activators, which suggests that these cells engage a non-canonical but ASC-dependent secretion pathway that does not rely on caspase-1 protease activity ([Figures 5](#fig5){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}C). However, wild-type cells secreted substantially more IL-1β than did *Casp1*^−/−^ and *Casp1*^*mlt/mlt*^ cells ([Figures 5](#fig5){ref-type="fig"}C and 5D), indicating that the efficiency of either IL-1β processing or IL-1β release is reduced in the absence of caspase-1 activity.

Inflammasome-Induced Lytic Cell Death and IL-1 Release in GSDMD-Deficient Cells {#sec2.6}
-------------------------------------------------------------------------------

Our data suggest that enhanced inflammasome-induced caspase-8 activation in the absence of caspase-1 was not merely a consequence of increased availability of potential binding sites on ASC and instead implied that the absence of caspase-1 protease activity or a consequence thereof permits caspase-8 activation at the inflammasome. Thus, we asked how caspase-1 protease activity suppresses caspase-8 activation at the inflammasome. Aside from itself, IL-1β, and GSDMD, caspase-1 has several other substrates that could potentially account for this phenomenon ([@bib1], [@bib9]). As expected, short-term (≤3 hr) stimulation with inflammasome activators triggered release of cleaved IL-1β and LDH from wild-type cells, but not from cells lacking GSDMD, caspase-1, or caspase-1 protease activity ([Figures 6](#fig6){ref-type="fig"}A and 6B). Similar to *Casp1*^−/−^ and *Casp1*^*mlt/mlt*^ cells and in contrast to wild-type cells, GSDMD-deficient cells displayed robust caspase-8 activation ([Figure 6](#fig6){ref-type="fig"}A). This indicates that caspase-1 activity results in the suppression of caspase-8 activation by inducing GSDMD-dependent pyroptosis. Gradual loss of intracellular caspase-8 was observed during GSDMD-dependent pyroptosis, and it is possible that this contributes to the reduced activation of caspase-8 in wild-type cells ([Figures 5](#fig5){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}D). However, inhibition of pyroptotic lysis in wild-type cells by addition of glycine ([@bib4]) did not restore caspase-8 activation ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E), suggesting that lysis is not the primary reason for suppression of inflammasome-induced caspase-8 activity in wild-type cells. Both caspase-1 and caspase-8 are activated in GSDMD-deficient cells, and this coincided with stronger intracellular cleavage of IL-1β (generating the bioactive p17 subunit) than was observed in cells lacking caspase-1 protease activity. Other caspase-dependent ([Figure S5](#mmc1){ref-type="supplementary-material"}D) IL-1β cleavage and degradation products were observed in cells lacking caspase-1 protease activity, but these were not released ([Figures 5](#fig5){ref-type="fig"}C and [6](#fig6){ref-type="fig"}A). IL-1β p17 was initially retained in cells; its delayed but robust GSDMD-independent release coincided with release of the lytic cell death marker LDH ([Figures 6](#fig6){ref-type="fig"}A and 6B) and the alarmin IL-1α ([Figure S6](#mmc1){ref-type="supplementary-material"}A). The late LDH release was comparable in GSDMD-deficient cells, in which both caspase-1 and caspase-8 are activated at the inflammasome, and in cells lacking caspase-1 protease activity, which suggests that this delayed, inflammasome-induced, LDH-releasing death in GSDMD-deficient cells is not driven by other potential substrates of caspase-1 ([Figure 6](#fig6){ref-type="fig"}B). In contrast, while the amount of IL-1β released from GSDMD-deficient cells eventually reached wild-type levels, cells lacking caspase-1 protease activity secreted less mature IL-1β even at late time points ([Figures 6](#fig6){ref-type="fig"}A and 6B), which is consistent with inefficient processing of IL-1β to the mature p17 form by caspase-8 ([@bib27]) and the observation of additional IL-1β cleavage and degradation bands in cells lacking caspase-1 activity. Altogether, these results indicate that ineffective proteolytic processing of IL-1β accounts for reduced levels of mature IL-1β in the supernatant of cells lacking caspase-1 activity, while the alternative secretion mechanism engaged by the inflammasome in the absence of GSDMD cleavage by caspase-1 leads to the robust release of IL-1. The preservation of a certain degree of IL-1 processing and secretion in GSDMD-deficient cells would suggest that defects in caspase-1 activity should have a stronger effect than GSDMD deficiency *in vivo*. GSDMD-deficient mice displayed a less severe phenotype than did caspase-1 knockout mice during *F. novicida* infection ([Figure 6](#fig6){ref-type="fig"}C).Figure 6GSDMD-Dependent Pyroptosis Suppresses Caspase-8 Activation(A) BMDCs of wild-type, *Gsdmd*^−/−^, B6-*Casp1*^−/−^, and B6-*Casp1*^*mlt/mlt*^ mice were analyzed by immunoblot for caspase-8 processing, as well as maturation and secretion of IL-1β after inflammasome activation by nigericin or poly(dA:dT) for 3, 9, or 18 hr.(B) Measurement of released IL-1β by ELISA and LDH by an enzymatic assay from samples in (A) (mean ± SEM are shown).(C) Following infection with *F. novicida* for 48 hr, bacterial loads in spleens (left) and livers (right) of wild-type, *Gsdmd*^−/−^, and B6.129-*Casp1* mice were determined by plating serial dilutions of organ homogenates on selective medium plates. The Mann-Whitney test was used for statistical analysis (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). Spleen: *Gsdmd*^−/−^ versus wild-type, p = 0.0017; *Gsdmd*^−/−^ versus B6.129-*Casp1*^−/−^, p = 0.0014; wild-type versus B6.129-*Casp1*^−/−^, p \< 0.0001; liver: *Gsdmd*^−/−^ versus wild-type, p = 0.0004; *Gsdmd*^−/−^ versus B6.129-*Casp1*^−/−^, p = 0.0189; wild-type versus B6.129-*Casp1*^−/−^, p \< 0.0001; wild-type, B6.129-*Casp1*^−/−^, and *Gsdmd*^−/−^: n = 16.(D) BMDCs from B6.129-*Casp1*^*mlt/mlt*^ mice on chambered coverslips were stimulated with nigericin or 10 μM raptinal and monitored for morphological changes over time by differential interference contrast (DIC) and fluorescence microscopy. Loss of membrane integrity was indicated by DRAQ7 (red) staining of DNA.(E) BMDCs of wild-type, B6.129-*Casp1*^−/−^, and *Pycard*^−/−^ mice were pretreated with the caspase inhibitors Z-VAD-fmk (20 μM), IETD-fmk (30 μM), or DEVD-fmk (30 μM) and subsequently stimulated with nigericin. Lytic cell death was quantified by LDH release as measured by an enzymatic assay after 4, 8, 12, and 16 hr.In (A) and (B), data are representative of 2 independent experiments.

We next investigated the mechanism of inflammasome-induced lytic cell death that was observed in cells incapable of GSDMD-dependent pyroptosis ([Table 1](#tbl1){ref-type="table"}). Previous studies have shown that caspase-8 activation in caspase-1-deficient cells treated with inflammasome activators correlates with features of apoptosis such as activation of executioner caspases, nuclear condensation, DNA fragmentation, and phosphatidylserine exposure ([@bib3], [@bib31], [@bib33], [@bib35]). Inflammasome activators triggered caspase-3 cleavage, PARP cleavage, and phosphatidylserine exposure in cells incapable of GSDMD-dependent pyroptosis ([Figures 6](#fig6){ref-type="fig"}A, [S6](#mmc1){ref-type="supplementary-material"}B, and S6C; [Table 1](#tbl1){ref-type="table"}). As expected, inducers of apoptosis such as raptinal and doxorubicin triggered blebbing before loss of membrane integrity ([Figures 6](#fig6){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}D). In contrast, cells incapable of GSDMD-dependent pyroptosis lost membrane integrity without prior blebbing upon treatment with inflammasome activators ([Figure 6](#fig6){ref-type="fig"}D). The loss of membrane integrity and the release of LDH by cells incapable of GSDMD-dependent pyroptosis indicate the existence of an alternative lytic cell death mechanism triggered by the inflammasome. The lack of blebbing suggests that this cell death pathway is not simply necrosis secondary to apoptosis, though the death modalities may employ the same upstream machinery. Several observations suggest that this lytic, inflammatory cell death pathway is not necroptosis: the robust activation of caspase-8 and caspase-3 ([Figure 6](#fig6){ref-type="fig"}A), the concomitant degradation of RIPK1 ([Figure S5](#mmc1){ref-type="supplementary-material"}A), and the insensitivity to necrostatin-1 ([Figure S6](#mmc1){ref-type="supplementary-material"}E). ASC deficiency markedly reduced lytic death at early and late phases, suggesting that the inflammasome platform is important not only for pyroptosis but also for this alternative lytic death pathway ([Figures 6](#fig6){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}C). A bioluminescence assay revealed strong activation of caspases in cells lacking caspase-1 protease activity ([Figure S6](#mmc1){ref-type="supplementary-material"}F). Furthermore, the pan-caspase inhibitor Z-VAD-fmk substantially (and to a lesser extent, the caspase-8 and caspase-3 inhibitors IETD-fmk and DEVD-fmk, respectively) reduced lytic death in cells lacking caspase-1 protease activity, suggesting that this form of cell death is driven by caspase activity ([Figure 6](#fig6){ref-type="fig"}E). The inability of these inhibitors to completely prevent lytic cell death is similar to the failure of peptide-based caspase-1 inhibitors to block GSDMD-dependent pyroptosis ([Figure 3](#fig3){ref-type="fig"}). Collectively, our data indicate that caspase-1 protease activity is required for pyroptosis and secretion of mature IL-1 at early time points after inflammasome activation. However, this study also demonstrates that in the absence of caspase-1 activity, the inflammasome activates caspase-8 and other caspases to trigger a GSDMD-independent secondary pyroptosis pathway as an alternative means to release mature IL-1.Table 1Summary of the Molecular and Cellular Features of Secondary Pyroptosis in Comparison to Other Forms of Cell DeathApoptosisNecroptosisPyroptosisSecondary PyroptosisSourceASC dependent−−++1, 2, 3, this manuscriptCaspase-1 dependent−−+−1, 2, 3, this manuscriptGSDMD dependent−−+−This manuscriptCell swelling−+++This manuscriptBlebbing, formation of apoptotic bodies+−−−This manuscriptLoss of membrane integrity (i.e., propidium iodide, DRAQ7 uptake)−+++1, 2, 3, this manuscriptCell lysis, LDH release−+++1, 3, this manuscriptPhosphatidylserine exposure+++++1, this manuscriptPore formation−+ MLKL+ GSDMDND[a](#tblfn1){ref-type="table-fn"}NDCaspase-8 activation+−−+1, 2, 3, this manuscriptCaspase-3 activation+−−+1, 2, 3, this manuscriptPARP cleavage++−+++This manuscriptDNA fragmentation++−(+)[b](#tblfn2){ref-type="table-fn"}+1, 2Nuclear condensation++++1, this manuscriptNEC1 sensitivity−+−−This manuscriptSensitive to caspase inhibitors+++(−)[c](#tblfn3){ref-type="table-fn"}±+This manuscriptIL-1 release−−++++3, this manuscript[^2][^3][^4][^5]

Discussion {#sec3}
==========

We have generated and analyzed mice expressing enzymatically inactive caspase-1^C284A^, which we have named *Casp1*^*mlt*^. In contrast to the previous observation that biochemical inhibition of caspase-1 by peptide-based inhibitors selectively blocks IL-1β cleavage but does not prevent pyroptosis or IL-1 secretion ([@bib6], [@bib8], [@bib17]), genetic inactivation of caspase-1 protease activity prevented not only IL-1β cleavage but also canonical IL-1 secretion and pyroptosis at early time points after inflammasome activation. The inability of Ac-YVAD-cmk to block cleavage of the pyroptotic effector GSDMD explains this discrepancy. The inhibition of both arms of caspase-1 inflammatory activity---IL-1 secretion and pyroptosis---was recapitulated by VX-765, a second-generation peptidomimetic inhibitor of caspase-1. Peptide-based caspase inhibitors can block apoptosis and have therefore been key tools in apoptosis research. In contrast, our results speak to the limited utility of such inhibitors in studying pyroptosis, because residual caspase activity and gasdermin processing are sufficient for lytic cell death.

Additional facets of the interplay between caspase-1 and caspase-8 at the inflammasome were revealed by analysis of *Casp1*^*mlt*^ mice. Although caspase-1^mlt^ strongly accumulated at the inflammasome, inflammasomes containing caspase-1^mlt^ recruited and activated caspase-8 as effectively as naked, caspase-1-deficient inflammasomes. This suggests that caspase-1, which is recruited to ASC by a homotypic caspase recruitment domain (CARD) interaction, does not compete with caspase-8 for the same binding sites on ASC in native myeloid cell inflammasomes. Structural studies and inflammasome reconstitution experiments in HEK293T cells showed that caspase-8 is recruited via its tandem DED domains to the PYD domain of ASC ([@bib14], [@bib31], [@bib35], [@bib41]). Mass spectrometry analysis of the inflammasome-enriched insoluble fraction demonstrated that ASC and caspase-1 were the most enriched proteins in this fraction. Detection of caspase-8 and other, less abundant components of the inflammasome will likely require improved enrichment methods.

Our data suggested that caspase-1 protease activity or its sequelae suppress caspase-8 activation at the inflammasome. Several substrates of caspase-1 have been identified ([@bib1], [@bib9]), but deficiency of GSDMD alone allowed for simultaneous activation of caspase-8 and caspase-1 at the inflammasome. These findings imply that GSDMD-dependent pyroptosis, rather than caspase-1 activity per se, precludes inflammasome-induced activation of caspase-8. Further studies will be necessary to mechanistically explain how pyroptosis inhibits caspase-8 activation at the inflammasome. Our finding that inhibiting pyroptotic lysis does not restore caspase-8 activation in wild-type cells suggests an active signaling event might be involved.

In cells lacking caspase-1, activation of caspase-8 at the inflammasome has been implicated in the non-canonical maturation of IL-1β ([@bib3], [@bib32]). We observed the same phenomenon in cells specifically lacking caspase-1 protease activity. In line with previous *in vitro* cleavage assays ([@bib27]), caspase-8-associated non-canonical processing of IL-1β in cells was less effective than caspase-1-mediated processing. In contrast to the rapid release of mature IL-1β from wild-type cells, IL-1β secretion from cells lacking caspase-1 protease activity was delayed. Despite this delay, GSDMD-deficient cells (in which caspase-1 is active) efficiently cleaved IL-1β and eventually released amounts of IL-1β equivalent to those released by wild-type cells. Thus, the non-canonical IL-1 release mechanism associated with caspase-8 activation and lytic cell death eventually compensated for the lack of rapid, caspase-1-driven, GSDMD-dependent release mechanisms. These findings also suggest that the ability of caspase-8 to contribute to IL-1-dependent inflammation may be limited by its inefficient cleavage of IL-1β. This is supported by our observation that intact caspase-1-mediated IL-1β processing in GSDMD-deficient mice correlates with enhanced protection of these mice relative to caspase-1-deficient mice during *Francisella* infection. Nonetheless, a role for caspase-8-driven non-canonical maturation and release of IL-1 in protection against infection is supported by previous *in vivo* studies showing that ASC-deficient mice (which lack both canonical and non-canonical IL-1 maturation and release pathways) are more susceptible to bacterial infection than caspase-1/11-deficient mice ([@bib32]). Collectively, these results suggest that alternative IL-1 maturation and release pathways contribute to immunity *in vivo*.

GSDMD-deficient cells are protected from caspase-11-driven cell death in response to intracellular LPS, even at late time points ([@bib22], [@bib38]). In contrast, we find that GSDMD-deficient cells treated with canonical activators that cause formation of an ASC-containing inflammasome are initially protected from cell death but lyse and release IL-1 after 8 hr. Though one possible explanation is that other caspase-1 cleavage targets mediate this alternative death pathway in GSDMD-deficient cells, our finding that delayed lytic death after inflammasome activation occurred with a similar strength and kinetics in GSDMD-deficient cells as in cells lacking caspase-1 protease activity demonstrates that caspase-1 protease activity is dispensable for this alternative lytic cell death modality. These results also raise the question of whether the formation of an ASC-containing inflammasome is a commitment to cell death. This issue may be worth considering in HIV infection, in which there is interest in using caspase-1 inhibitors to prevent pathogenic depletion of unproductively infected CD4^+^ T cells ([@bib11]). The inflammasome can serve as a platform for caspase-8 activation in CD4^+^ T cells, so even effective caspase-1 inhibitors such as VX-765 may only delay HIV-induced death of these cells by diverting them to the slower alternative death pathway associated with caspase-8 activation ([@bib28]). Therefore, in conditions such as HIV infection, cryopyrin-associated periodic syndromes, and sepsis, in which pyroptosis is implicated in pathogenic inflammation or cell depletion ([@bib7], [@bib21]), it may be more effective to develop strategies to prevent formation of the inflammasome.

The inflammasome-induced delayed lytic cell death observed in cells incapable of GSDMD-dependent pyroptosis was driven by activation of caspase-8. Caspase-8 initiates the extrinsic apoptosis pathway by cleaving executioner caspases, which in turn degrade cellular proteins and kill the cell. Apoptosis is defined as an immunologically silent form of cell death; it preserves plasma membrane integrity and therefore does not release inflammatory cytokines or alarmins. Regulated necrosis pathways---including necroptosis, pyroptosis, and several other recently discovered cell death modalities---cause cell lysis but, in contrast to passive necrosis, are genetically controlled. Previous studies have classified inflammasome-induced cell death in caspase-1-deficient cells as apoptosis based on the observation of caspase-3 cleavage, phosphatidylserine exposure, nuclear condensation, and DNA degradation ([@bib3], [@bib31], [@bib33], [@bib35]). Yet in contrast to apoptosis, inflammasome-induced cell death in cells lacking caspase-1 protease activity was lytic and released large amounts of IL-1. Its requirement for upstream inflammasome components and its sensitivity to caspase inhibition demonstrate regulation. However, the lack of apoptotic blebbing before lysis suggests that this necrotic pathway was not simply secondary to apoptosis and therefore may represent a distinct form of regulated necrosis. On the basis of its specific features and its delay relative to canonical, caspase-1-dependent pyroptosis ([Table 1](#tbl1){ref-type="table"}), this lytic, inflammasome-dependent cell death might be considered a non-canonical or secondary form of pyroptosis. This adds another form of cell death to those already linked to caspase-8, raising the question how a molecule like caspase-8 has evolved such roles in diverse forms of cell death, including apoptosis, necroptosis, and secondary pyroptosis. This will be an intriguing topic for further study. The pore-forming gasdermin family member DFNA5 ([@bib10]) was identified as a substrate of caspase-3 that executes secondary necrosis ([@bib34]) and lytic cell death in response to chemotherapeutics ([@bib42]). DFNA5 is cleaved in parallel to other caspase substrates, so cell-type-specific differences in the balance of DNFA5 and executioners of apoptosis may govern the relative kinetics of classical apoptosis and regulated necrosis driven by apoptotic caspases. Cleavage of DFNA5 by caspase-3 may represent a mechanism by which caspase-8 activation at the inflammasome can cause secondary pyroptosis, but further research will be required to address this and other possible mechanisms.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

*Nlrp3*^−/−^, B6.129-*Casp1/11*^−/−^ ([@bib23]), B6.C-Tg(CMV-cre)1^Cgn^/J, *GSDMD*^−/−^, B6-*Casp1*^*mlt/mlt*^, B6.129-*Casp1*^*mlt/mlt*^, and B6-*Casp1*^−/−^ mice were housed under SPF or SOPF conditions at the Zentrum für Präklinische Forschung (Munich, Germany), Charles River Laboratories (Italy), or the Biozentrum, University of Basel (Switzerland), in accordance with local and European guidelines, as well as Federation for Laboratory Animal Science Associations (FELASA) recommendations. *Casp1*^*mlt*^ mice were generated by conventional gene targeting in both C57BL/6 and 129 genetic backgrounds, and *Casp1*- and *GSDMD*-deficient mice were generated by CRISPR/Cas9 technology, as described in detail in the [Supplemental Information](#app2){ref-type="sec"}.

Reagents {#sec4.2}
--------

All tissue culture reagents were from Invitrogen, unless indicated otherwise. Toll-like receptor (TLR) ligands were from InvivoGen. Raptinal was from AdipoGen Life Sciences. All other chemicals and reagents were from Sigma, unless indicated otherwise. Sources and identifiers of the antibodies used can be found in the [Supplemental Information](#app2){ref-type="sec"}. *Salmonella enterica* subspecies I serovar Typhimurium X3625 (ΔaroA) (*Salmonella enterica* serovar Typhimurium) was a gift from Bärbel Stecher, Munich. Kits used for cloning were from Promega.

Inflammasome Activation and Analysis {#sec4.3}
------------------------------------

BMDCs were generated and stimulated as previously described ([@bib18], [@bib37]). Cells were primed with 50 ng/mL of ultrapure LPS for 3 hr, and inhibitors were added 30 min before stimulation with inflammasome activators at optimal concentrations, as outlined in the [Supplemental Information](#app2){ref-type="sec"}. Stimulation with nigericin was performed with a final concentration of 5--10 μM and for a duration of 45--60 min. ELISA, immunoblot analysis, and other measurements were performed as described in detail in the [Supplemental Information](#app2){ref-type="sec"}.

Animal Infection {#sec4.4}
----------------

Infection of mice with wild-type *F. novicida* strain U112 was performed at the Biozentrum, University of Basel. All animal experiments were approved (license 2535-26742, Kantonales Veterinäramt Basel-Stadt) and were performed according to local guidelines (Tierschutz-Verordnung, Basel-Stadt) and the Swiss animal protection law (Tierschutz-Gesetz). Bacteria were cultured overnight in brain heart infusion (BHI) medium (supplemented with 100 μg/mL ampicillin \[AppliChem\] and 0.2% L-cysteine). Bacteria were harvested by centrifugation and washed once with 1× Dulbecco's Phosphate-Buffered Saline (DPBS). Mice were infected subcutaneously with 5 × 10^3^ CFU in 50 μL 1× DPBS. Infected mice had access to food and water *ad libitum*. Mice were sacrificed 48 hr after infection, and spleen and liver were harvested. Colony-forming units (CFUs) were determined from spleen and liver homogenates plated in serial dilutions on Mueller-Hinton agar plates supplemented with 0.1% D-glucose (Millipore), 0.1% fetal calf serum (FCS) (BioConcept), 100 μg/mL ampicillin (AppliChem), and 0.1% L-cysteine. Statistical analysis was performed using GraphPad Prism 6.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S6Document S2. Article plus Supplemental Information
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[^1]: Lead Contact

[^2]: The source column refers to the description of cell death induced by the inflammasome but independent of caspase-1. Previous reports characterized this cell death as apoptosis: (1) [@bib31], (2) [@bib35], and (3) [@bib3].

[^3]: The effector of secondary pyroptosis remains to be investigated but is potentially another gasdermin.

[^4]: NLRC4 activation by bacteria was observed to be accompanied by DNA fragmentation and laddering in wild-type cells ([@bib29]). In contrast, (1) [@bib31] and (2) [@bib35] did not observe this phenomenon after stimulation of the AIM2 or NLRP3 inflammasome, respectively, in wild-type or ASC-deficient cells but instead only observed it in the absence caspase-1.

[^5]: Necroptosis occurs when caspase-8 is inhibited.
